Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle

Pirnay, G.; Dantier, B.; Tourid, W.; Terkemani, A.; Bachot, F.; Hadim, L.; Abdous, N.; Amara, W.; Abrous, Z.; Bozel, A.; Gaubert-Dahan, Marie-Line; Aikpa, Raoul; Fauvelle, F.

doi:10.1016/j.phclin.2020.06.001

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some studies have also shown that chloroquine reduces fever and leads to an improvement in the CT signs on imaging, as well as delaying the progression of symptoms. This has led some Chinese researchers to recommend a chloroquine-based treatment for COVID-19, of all severities [7,8].…”

Section: Hydroxychloroquine and Azithromycinmentioning

confidence: 99%

The main treatments used for SARS-CoV-2 patients

MERGHACHE¹

2022

Alger. j. biosciences

View full text Add to dashboard Cite

As the COVID-19 pandemic continues to ravage the world and threaten people's lives, treating infected patients effectively has been one of the top concerns for medical workers around the world. Currently, no medication is recommended to treat COVID-19, and no cure is available. Researchers are testing a variety of possible treatments. Several drugs are being researched in different countries. Most are existing drugs that are being trialled against the virus. Pharmaceuticals undergoing clinical trials to assess their safety and efficacy as potential treatments for COVID-19, include the antiviral nucleotide analogue remdesivir, systemic interferons and in particular interferon β-1a, the antiviral combination lopinavir/ritonavir, the antimalarial chloroquine/hydroxychloroquine, and monoclonal antibodies against components of the immune system such as interleukin-6 (IL-6) and IL-4. It is important that the potential treatments are carefully assessed in randomised controlled trials..

show abstract

Section: Hydroxychloroquine and Azithromycinmentioning

confidence: 99%

The main treatments used for SARS-CoV-2 patients

MERGHACHE¹

2022

Alger. j. biosciences

View full text Add to dashboard Cite

show abstract

Azithromycin/hydroxychloroquine

2021

Reactions Weekly

View full text Add to dashboard Cite

Azithromycin/hydroxychloroquine QTc prolongation following off-label use: 2 case reports In a non-randomised observational study of 68 elderly patients, treated with azithromycin and hydroxychloroquine at a hospital in France between 27 March 2020 and 1 May 2020, two elderly patients aged > 65 years [exact ages not stated; sexes not stated] were described, who experienced prolongation of QTc during off-label therapy with azithromycin and hydroxychloroquine for COVID-19. Both patients, who were hospitalised due to COVID-19, started receiving off-label therapy with oral hydroxychloroquine [Plaquenil] tablet 200mg three times a day scheduled for 10 days, and oral azithromycin [Zithromax] tablet at a dose of 500mg on the first day followed by 250mg for 4 days. Subsequently, both patients experienced prolongation of QTc to > 450ms, which was attributed to the off-label therapy with azithromycin and hydroxychloroquine [times to reactions onsets not clearly stated]. Therefore, one patient discontinued the treatment after three days of therapy, while the other patient discontinued the treatment after nine days [outcomes not stated].

show abstract

Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection

Boretti

2021

Asian J. Chem.

View full text Add to dashboard Cite

This work summarizes the available evidence of the use of chloroquine/hydroxychloroquine (CQ/HCQ) in SARS-CoV-2 infection. Most of the published works indicate CQ/HCQ is likely effective against SARS-CoV-2 infection, almost 100% in prophylaxis and mild-medium severity cases and 60% in late infection cases. The percentage of positive works is larger if those works conducted under a probable conflict of interest are excluded from the list. Despite this overwhelming evidence from independent studies, the use of CQ/HCQ is currently limited or prevented in many western countries, based on a very singular examination of the science. The case of a work published in late May 2020, despite being openly defective and then retracted, prompted the World Health Organization (WHO) to ban the use of CQ/HCQ. This position has not yet rectified, thanks to the results of the not less questionable RECOVERY trial, where very sick patients were administered more than double the dose, over more than double the time, recommended for asymptomatic patients in current protocols of other countries, where CQ/HCQ are used for asymptomatic and mild but not severe pneumonia critically ill patients. While the case fatality rate does not depend only on therapies, it is finally shown based on the number of cases and fatalities per million and the case fatality rate as the western countries enforcing the ban on CQ/HCQ did not perform better, but much worse, than other countries, also because of therapies.

show abstract

Effet bénéfique de l’association hydroxychloroquine/azithromycine dans le traitement des patients âgés atteints de la COVID-19 : résultats d’une étude observationnelle

Cited by 4 publications

References 3 publications

The main treatments used for SARS-CoV-2 patients

The main treatments used for SARS-CoV-2 patients

Azithromycin/hydroxychloroquine

Safety and Efficacy of Chloroquine/Hydroxychloroquine in SARS-CoV-2 Infection

Contact Info

Product

Resources

About